Eli Lilly & Co. cuts price of popular diabetes and weight-loss drugs in Canada
The Price of Progress: How Drug Price Regulation and Generic Competition are Reshaping the Weight-Loss Drug Market Eli Lilly’s recent decision to slash prices on Mounjaro and Zepbound in Canada isn’t a simple act of corporate generosity. It’s a calculated move responding to a confluence of factors: impending drug price regulations, the looming arrival of … Read more